Skip to content
The BCI Briefing

Company profileCore BCI

Neuralink

A fully implanted, wireless intracortical BCI placed by a surgical robot.

Location
Fremont, United States
Founded
2016
Funding stage
Series E
Sources last checked
6 Oct 2026

What they are building

Builds the N1 Implant, a cranially mounted device with flexible electrode threads inserted into cortex by the R1 robot.

Interface category
Intracortical arrays
Signal
Action potentials and local field potentials
Invasiveness
Invasive
Recording / stimulation
Recording
Device
N1 Implant — Skull-mounted implant with flexible polymer threads, inserted by the R1 surgical robot
Channels
1,024 electrodes
Regulatory status
Investigational; in early feasibility studies
Main use cases
Control, Communicate

Where they are clinically

Feasibility

Small early studies that test safety and whether the device can do what it is meant to.

Access today

Clinical study

Accessible only by enrolling in a registered clinical study.

Shown in people
Home use of a fully implanted, wireless intracortical device for cursor control. The rates reported, up to 11.32 bits per second, are the company's own figures; no clinical result from the PRIME studies is peer reviewed.
Still an aim
Restoring communication for people who cannot speak. The VOICE study, registered for six participants, began in October 2025 and has not reported.
What stands in the way
Evidence others can check: peer-reviewed safety and performance data, and a registered pivotal trial.

On record here: 5 registered studies · 44 participants planned or enrolled · 0 peer-reviewed papers

This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.

Why this company matters

Neuralink is running the broadest registered study programme of any implanted-BCI company, across four countries, and its home-use data volume is now large enough to pretrain decoders. Almost all of its performance results are company-reported; peer-reviewed clinical data would let the field weigh them against academic benchmarks.

Key milestones

  1. 1 Oct 2026

    Company reports a cursor-control rate of 11.32 bits per second after pretraining decoders on more than 50,000 hours of participant data.

    Tesla North

  2. 3 Oct 2025

    VOICE early feasibility study for communication restoration begins.

    VOICE · NCT07224256

  3. Jun 2025

    Series E of $650M reported.

    Neurofounders

  4. 20 Nov 2024

    CAN-PRIME study begins in Canada; further PRIME studies follow in the UAE and UK during 2025.

    CAN-PRIME · NCT06700304

  5. 9 Jan 2024

    PRIME early feasibility study begins in the United States.

    PRIME · NCT06429735

  6. 8 Aug 2023

    Series D of $280M led by Founders Fund, announced by the company.

    TechNode Global

  7. 31 Oct 2019

    White paper describes flexible electrode threads and a robotic inserter.

    Musk E et al., Journal of Medical Internet Research

Clinical programmes

  • VOICE

    Extends the N1 Implant to speech and communication restoration.

    FeasibilityRecruiting

    6 estimatedNCT07224256

  • GB-PRIME

    UK arm of the PRIME programme.

    FeasibilityRecruiting

    7 estimatedNCT07127172

  • UAE-PRIME

    United Arab Emirates arm of the PRIME programme.

    FeasibilityRecruiting

    10 estimatedNCT06992596

  • CAN-PRIME

    Canadian arm of the PRIME programme.

    FeasibilityRecruiting

    6 estimatedNCT06700304

  • PRIME

    Early feasibility study of the N1 Implant and R1 Robot for control of external devices.

    FeasibilityRecruiting

    15 estimatedNCT06429735

Research

Funding history

  • Jun 2025$650MSeries EAmount confirmed in reporting; investor list recorded from the company announcement and awaiting a re-check.
  • 8 Aug 2023$280MSeries D · led by Founders Fund

Investors namedARK Invest · Founders Fund · Sequoia Capital · Thrive Capital · Qatar Investment Authority · Lightspeed Venture Partners

Rounds in the Briefing’s sample only; not a complete funding history.

Leadership

  • Elon Musk

    Co-founder

As publicly stated by the organisation. Not a complete list.

IP and patents

Filings spread across 9 of the 11 layers, most often interface and electrodes (17 of 31 families) and implant electronics (10).

31
patent families identified and counted as BCI
2018
earliest first filing among them
21
first filed since 2021; the latest years are incomplete
24 of 31
include a granted member, of those whose family record was read

Across the stack: families by layer

Themes, by number of families: electrodes and arrays (17), surgical planning and procedure (7), chips and on-implant computing (7), packaging and hermeticity (7), insertion tools and robots (6), stimulation (6). A family can carry several.

Published in: United States (30), Japan (7), South Korea (7), Australia (4), Canada (4), counted over the 31 families whose full record was read.

25 more families counted

Families found for Neuralink in the EPO’s worldwide database, grouped so that one invention counts once. A filing shows what a company sought to protect. It does not show that the technology was built, is in a product, or works in people, and themes are read from titles, abstracts and classes, not from the claims. How to read this

Competitive context

Latest BCI Briefing coverage

Sources

  1. 01

    Neuralink Sets New BCI Record After Training on 50,000 Hours of Brain Data (opens in a new tab)

    Independent reportingTesla North2 Oct 2026Checked against source 3 Oct 2026

    Secondary report of a Neuralink blog post dated 1 October 2026.

  2. 02

    Neuralink — Updates (opens in a new tab)

    Company reportedNeuralink1 Oct 2026Source identified, not opened

    Primary company post could not be retrieved automatically; figures are taken from secondary reporting of it.

  3. 03

    Musk's Neuralink raises $280M in funding led by Thiel's Founders Fund (opens in a new tab)

    Independent reportingTechNode Global8 Aug 2023Checked against source 6 Oct 2026

    Reports the company's own announcement of the round.

  4. 04

    Musk E et al. J Med Internet Res 2019;21(10):e16194 (opens in a new tab)

    Company reportedJournal of Medical Internet Research31 Oct 2019Checked against source 3 Oct 2026

    DOI 10.2196/16194

  5. 05

    ClinicalTrials.gov NCT06429735 (opens in a new tab)

    Clinical registryClinicalTrials.gov9 Jan 2026Checked against source 3 Oct 2026

    Registry record last updated 2026-01-09.

  6. 06

    ClinicalTrials.gov NCT06700304 (opens in a new tab)

    Clinical registryClinicalTrials.gov31 May 2025Checked against source 3 Oct 2026

    Registry record last updated 2025-05-31.

  7. 07

    BCI Funding Reaches A New Scale In 2026 (opens in a new tab)

    Independent reportingNeurofoundersChecked against source 3 Oct 2026

    Lists round sizes; does not give lead investors or dates.

  8. 08

    ClinicalTrials.gov NCT07224256 (opens in a new tab)

    Clinical registryClinicalTrials.gov4 Nov 2025Checked against source 3 Oct 2026

    Registry record last updated 2025-11-04.